Bafna Pharmaceuticals Share Price | Bafna Pharmaceuticals Stock Screener
BAFNAPH
Pharmaceuticals
Share Price NSE
₹135.30
▲
0.00 (0.00%)
Share Price BSE
₹137.00
▼
-1.00 (-0.72%)
As of May 18, 2026, the Bafna Pharmaceuticals share price (NSE: BAFNAPH) is ₹135.30 on NSE and ₹137.00 on BSE, unchanged from the previous close, with shares trading between ₹134.90 and ₹140.90, and a 52-week range of ₹72.93–₹140.91.
Check BAFNAPH annual price range for the annual price range and momentum.
Use the Bafna Pharmaceuticals stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Bafna Pharmaceuticals Market Cap
₹320.07 Cr.
BAFNAPH P/E Ratio (TTM)
15.00
Bafna Pharmaceuticals P/B Ratio
6.39
EPS (TTM)
₹-15.52
Dividend Yield
-
Debt to Equity
0.70
BAFNAPH 52 Week High
₹140.91
Bafna Pharmaceuticals 52 Week Low
₹72.93
Operating Margin
-42.00%
Profit Margin
-28.57%
BAFNAPH Revenue (TTM)
₹7.00
EBITDA
₹-3.00
Net Income
₹-2.00
Total Assets
₹71.00
Total Equity
₹51.00
Bafna Pharmaceuticals Share Price Chart
Screen Bafna Pharmaceuticals share price with an interactive chart. Analyse BAFNAPH price trends and volatility across different timeframes.
Bafna Pharmaceuticals Company Profile - Fundamental Screener
Screen Bafna Pharmaceuticals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for BAFNAPH shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE878I01022
Bafna Pharmaceuticals Balance Sheet Screener
Screen BAFNAPH balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Total Assets | 71 | 120 | 138 | 178 | 193 | 200 |
| Current Assets | 36 | 49 | 49 | 77 | 123 | 127 |
| Fixed Assets | 35 | 37 | 45 | 49 | 53 | 55 |
| Liabilities | ||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 3 | 30 | 41 | 55 | 40 | 16 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||
| Total Equity | 51 | 19 | 37 | 42 | 58 | 73 |
| Share Capital | 2 | 24 | 24 | 19 | 19 | 19 |
| Reserves & Surplus | -7 | -5 | 14 | 20 | 39 | 53 |
Bafna Pharmaceuticals Income Statement Screener - Profit & Revenue Analysis
Screen Bafna Pharmaceuticals income statement and profit fundamentals.
Analyze BAFNAPH quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Bafna Pharmaceuticals share price evaluation.
| Item | 2019-Jun | 2019-Sept | 2018-Jun | 2018-Sept |
|---|---|---|---|---|
| Revenue | 7 | 12 | 12 | 9 |
| Expenses | 10 | 12 | 14 | 9 |
| EBITDA | -3 | 0 | -2 | 0 |
| Operating Profit % | -42.00% | -3.00% | -15.00% | 2.00% |
| Depreciation | 1 | 1 | 1 | 1 |
| Interest | 0 | 0 | 1 | 1 |
| Profit Before Tax | -4 | -1 | -4 | -1 |
| Tax | -2 | 0 | 0 | 0 |
| Net Profit | -2 | -1 | -4 | -1 |
| EPS | -0.90 | -0.25 | 0.00 | -0.80 |
Bafna Pharmaceuticals Cash Flow Screener - Liquidity Fundamentals
Screen BAFNAPH cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|
| Operating Activities | -34 | -2 | -7 | -1 | 1 | 11 |
| Investing Activities | 33 | 15 | 38 | -5 | 0 | 60 |
| Financing Activities | 7 | -14 | -31 | 6 | -1 | -71 |
| Net Cash Flow | 6 | 0 | 0 | 0 | 0 | 0 |
Bafna Pharmaceuticals Shareholding Pattern Screener
See Bafna Pharmaceuticals shareholding pattern with promoter, FII, and DII holdings.
Check Bafna Pharmaceuticals promoter holding and ownership changes for BAFNAPH on TickJournal.
| Item | 2026-Mar | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 88.30% | 88.30% | 88.30% |
| FII Holding | 9.34% | 8.53% | 9.34% | 9.34% | 9.34% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 12.13% | 11.06% | 11.62% | 12.03% | 12.13% | 7.48% | 7.37% | 7.69% |
| Other Holding | 3.53% | 5.40% | 4.04% | 3.63% | 3.53% | 4.23% | 4.34% | 4.01% |
| Shareholder Count | 6,928 | 7,142 | 7,283 | 7,572 | 7,119 | 7,539 | 7,391 | 7,295 |
Bafna Pharmaceuticals Share Dividend Screener - Share Yield Analysis
Check Bafna Pharmaceuticals dividend history with payout and yield data.
View Bafna Pharmaceuticals dividend details including ex-dates and amounts for BAFNAPH stock.
Bafna Pharmaceuticals Stock Index Membership
See which indices include Bafna Pharmaceuticals stock.
Check BAFNAPH index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Bafna Pharmaceuticals Market Events Screener - Corporate Actions
Get Bafna Pharmaceuticals corporate actions including splits, bonuses, and buybacks.
Check Bafna Pharmaceuticals stock events that may affect BAFNAPH share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | 43.07% | ||
| Annual General Meeting | NA | -2.66% | ||
| 2026-02-11 | 2026-02-11 | Quarterly Result Announcement | NA | 6.76% |
| 2025-11-11 | 2025-11-11 | Quarterly Result Announcement | NA | 12.98% |
| 2025-08-12 | 2025-08-12 | Quarterly Result Announcement | NA | 10.01% |
| 2025-05-26 | 2025-05-26 | Quarterly Result Announcement | NA | -5.05% |
| 2025-02-06 | 2025-02-06 | Quarterly Result Announcement | NA | 0.76% |
| 2024-11-11 | 2024-11-11 | Quarterly Result Announcement | NA | 2.21% |
Bafna Pharmaceuticals Competitors Screener - Peer Comparison
Screen BAFNAPH competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 450,643 | 40.81 | 54,729 | 9.71% | 10,980 | 64.89 |
| Divis Laboratories | 179,470 | 74.13 | 9,712 | 18.67% | 2,191 | 64.06 |
| Torrent Pharmaceuticals | 149,109 | 65.68 | 11,539 | 6.99% | 1,911 | 58.52 |
| Cipla | 115,682 | 30.09 | 27,712 | -2.46% | 3,783 | 69.78 |
| Dr Reddys Laboratories | 111,567 | 26.16 | 33,593 | -0.44% | 3,998 | 59.87 |
| Lupin | 104,032 | 19.28 | 27,488 | 19.98% | 5,345 | 46.11 |
| Mankind Pharma | 103,325 | 56.36 | 12,744 | 20.90% | 2,007 | 73.37 |
| Zydus Life Science | 101,801 | 19.85 | 23,511 | 18.55% | 4,615 | 69.47 |
| Aurobindo Pharma | 87,806 | 25.16 | 32,346 | 9.43% | 3,484 | 73.83 |
| Laurus Labs | 71,455 | 79.78 | 6,813 | 21.03% | 884 | 80.26 |
Bafna Pharmaceuticals Company Announcements - News Screener
Screen BAFNAPH latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-04-15 | Clarification On Price Movement | - |
| 2026-04-13 | Clarification sought from Bafna Pharmaceuticals Ltd | - |
| 2026-04-13 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-03-27 | Board Meeting Outcome for Outcome For Board Meeting Held On 27/03/2026 | - |
| 2026-03-26 | Closure of Trading Window | - |
| 2026-03-24 | Clarification On Price Movement | - |
| 2026-03-23 | Clarification sought from Bafna Pharmaceuticals Ltd | - |
| 2026-02-14 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-02-11 | Unaudited Financial Results For The Quarter And Nine Months Ended On December 31 2025 | - |
| 2026-02-11 | Board Meeting Outcome for Outcome For The Board Meeting Held On 11/02/2026 | - |
| 2026-02-05 | Board Meeting Intimation for Meeting Scheduled On February 11 2026 | - |
| 2026-01-23 | Announcement under Regulation 30 (LODR)-Credit Rating | - |
| 2026-01-09 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2025-12-26 | Closure of Trading Window | - |
| 2025-11-14 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2025-11-11 | Unaudited Financial Results For The Quarter And Half Year Ended September 30 2025 | - |
| 2025-11-11 | Board Meeting Outcome for Outcome For The Board Meeting Held On 11/11/2025 | - |
| 2025-11-06 | Board Meeting Intimation for Meeting Scheduled On November 11 2025 | - |
| 2025-10-10 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2025-09-26 | Closure of Trading Window | - |